BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36237332)

  • 1. Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Wang M; Ping H
    Front Oncol; 2022; 12():981226. PubMed ID: 36237332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Ping H
    Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
    Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
    Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
    Xu Z; Chen S; Zhang Y; Liu R; Chen M
    Front Immunol; 2022; 13():869759. PubMed ID: 35603206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
    Chen L; Zhang M; Zhou J; Zhang L; Liang C
    Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 7. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
    Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
    Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Prostate Cancer Risk Genetics Biomarkers Based on Intergraded Bioinformatics Analysis.
    Liang X; Wang Y; Pei L; Tan X; Dong C
    Front Surg; 2022; 9():856446. PubMed ID: 35372462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
    Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
    Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
    [No Abstract]   [Full Text] [Related]  

  • 11. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
    Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
    Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Liang Y; Zhang X; Ma C; Hu J
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer.
    Zhang Q; Luan J; Song L; Wei X; Xia J; Song N
    J Cancer; 2021; 12(12):3575-3586. PubMed ID: 33995635
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
    Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
    Front Immunol; 2022; 13():914577. PubMed ID: 35757739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
    Jiao M; Zhang F; Teng W; Zhou C
    Int J Gen Med; 2022; 15():3003-3030. PubMed ID: 35313552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Hypoxia-Related Gene Signature with Strong Predicting Ability in Non-Small-Cell Lung Cancer Identified by Comprehensive Profiling.
    Yang H; Wang Z; Gong L; Huang G; Chen D; Li X; Du F; Lin J; Yang X
    Int J Genomics; 2022; 2022():8594658. PubMed ID: 35634481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.